TY - JOUR
T1 - Prenatal exposure to serotonin reuptake inhibitors and congenital heart anomalies
T2 - An exploratory pharmacogenetics study
AU - Daud, Aizati N A
AU - Bergman, Jorieke E H
AU - Kerstjens-Frederikse, Wilhelmina S
AU - van der Vlies, Pieter
AU - Hak, Eelko
AU - Berger, Rolf M F
AU - Groen, Henk
AU - Wilffert, Bob
PY - 2017/7/1
Y1 - 2017/7/1
N2 - Aim: To explore the role of pharmacogenetics in determining the risk of congenital heart anomalies (CHA) with prenatal use of serotonin reuptake inhibitors. Methods: We included 33 case-mother dyads and 2 mother-only (child deceased) cases of CHA in a case-only study. Ten genes important in determining fetal exposure to serotonin reuptake inhibitors were examined: CYP1A2, CYP2C9, CYP2C19, CYP2D6, ABCB1, SLC6A4, HTR1A, HTR1B, HTR2A and HTR3B. Results: Among the exposed cases, polymorphisms that tended to be associated with an increased risk of CHA were SLC6A4 5-HTTLPR and 5-HTTVNTR, HTR1A rs1364043, HTR1B rs6296 and rs6298 and HTR3B rs1176744, but none reached statistical significance due to our limited sample sizes. Conclusion: We identified several polymorphisms that might potentially affect the risk of CHA among exposed fetuses, which warrants further investigation.
AB - Aim: To explore the role of pharmacogenetics in determining the risk of congenital heart anomalies (CHA) with prenatal use of serotonin reuptake inhibitors. Methods: We included 33 case-mother dyads and 2 mother-only (child deceased) cases of CHA in a case-only study. Ten genes important in determining fetal exposure to serotonin reuptake inhibitors were examined: CYP1A2, CYP2C9, CYP2C19, CYP2D6, ABCB1, SLC6A4, HTR1A, HTR1B, HTR2A and HTR3B. Results: Among the exposed cases, polymorphisms that tended to be associated with an increased risk of CHA were SLC6A4 5-HTTLPR and 5-HTTVNTR, HTR1A rs1364043, HTR1B rs6296 and rs6298 and HTR3B rs1176744, but none reached statistical significance due to our limited sample sizes. Conclusion: We identified several polymorphisms that might potentially affect the risk of CHA among exposed fetuses, which warrants further investigation.
KW - gene-environment interaction
KW - heart defects
KW - pharmacogenetics
KW - serotonin reuptake inhibitors
KW - teratogenicity
KW - GENE-ENVIRONMENT INTERACTIONS
KW - ANTIDEPRESSANT THERAPY
KW - P-GLYCOPROTEIN
KW - ABCB1 GENE
KW - PROMOTER POLYMORPHISM
KW - CLINICAL-RESPONSE
KW - MAJOR DEPRESSION
KW - PREGNANT-WOMEN
KW - MEDICATION USE
KW - RISK-FACTORS
U2 - 10.2217/pgs-2017-0036
DO - 10.2217/pgs-2017-0036
M3 - Article
C2 - 28639488
SN - 1462-2416
VL - 18
SP - 987
EP - 1001
JO - Pharmacogenomics
JF - Pharmacogenomics
IS - 10
ER -